The late-cycle meeting required by the US FDA user fee review program cemented Array BioPharma Inc.’s decision to withdraw its new drug application (NDA) for the oncologic binimetinib (MEK162) ahead of an advisory committee review.
On March 17, Array withdrew the NDA for binimetinib, a MEK inhibitor, for monotherapy treatment of NRAS-mutant melanoma. The withdrawal...







